DE69129126D1 - Neue pharmazeutische formulierungen von 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol - Google Patents

Neue pharmazeutische formulierungen von 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol

Info

Publication number
DE69129126D1
DE69129126D1 DE69129126T DE69129126T DE69129126D1 DE 69129126 D1 DE69129126 D1 DE 69129126D1 DE 69129126 T DE69129126 T DE 69129126T DE 69129126 T DE69129126 T DE 69129126T DE 69129126 D1 DE69129126 D1 DE 69129126D1
Authority
DE
Germany
Prior art keywords
methylthiazole
hydroxyethyl
pharmaceutical formulations
chlorine
new pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129126T
Other languages
English (en)
Other versions
DE69129126T2 (de
Inventor
Bernard Robin Boar
Alan John Cross
Alfred Richard Green
Curt-Eric Hagberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of DE69129126D1 publication Critical patent/DE69129126D1/de
Publication of DE69129126T2 publication Critical patent/DE69129126T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69129126T 1990-08-15 1991-08-07 Neue pharmazeutische formulierungen von 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol Expired - Lifetime DE69129126T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations
PCT/SE1991/000522 WO1992003134A1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole

Publications (2)

Publication Number Publication Date
DE69129126D1 true DE69129126D1 (de) 1998-04-23
DE69129126T2 DE69129126T2 (de) 1998-07-23

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129126T Expired - Lifetime DE69129126T2 (de) 1990-08-15 1991-08-07 Neue pharmazeutische formulierungen von 5-(2-chlor-1-hydroxyethyl)-4-methylthiazol

Country Status (26)

Country Link
US (1) US5385921A (de)
EP (1) EP0619734B1 (de)
JP (1) JP3094077B2 (de)
AT (1) ATE164066T1 (de)
AU (1) AU657490B2 (de)
BG (1) BG97446A (de)
CA (1) CA2088775A1 (de)
CZ (1) CZ279586B6 (de)
DE (1) DE69129126T2 (de)
DK (1) DK0619734T3 (de)
ES (1) ES2114891T3 (de)
FI (1) FI930608A (de)
HU (1) HUT65821A (de)
IE (1) IE912818A1 (de)
IL (1) IL99169A (de)
IS (1) IS3743A7 (de)
LT (1) LT3978B (de)
LV (1) LV10921B (de)
NO (1) NO303447B1 (de)
NZ (1) NZ239329A (de)
PT (1) PT98688B (de)
RO (1) RO112994B1 (de)
RU (1) RU2093155C1 (de)
SE (1) SE9002659D0 (de)
SK (1) SK8793A3 (de)
WO (1) WO1992003134A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
ES2114891T3 (es) 1998-06-16
HUT65821A (en) 1994-07-28
ATE164066T1 (de) 1998-04-15
NO303447B1 (no) 1998-07-13
IL99169A (en) 1995-10-31
SE9002659D0 (sv) 1990-08-15
SK8793A3 (en) 1993-07-07
LV10921B (en) 1996-08-20
IS3743A7 (is) 1992-02-16
CA2088775A1 (en) 1992-02-16
DE69129126T2 (de) 1998-07-23
DK0619734T3 (da) 1998-10-05
NO930452L (no) 1993-02-09
FI930608A0 (fi) 1993-02-11
JPH06500097A (ja) 1994-01-06
AU8409291A (en) 1992-03-17
RU2093155C1 (ru) 1997-10-20
RO112994B1 (ro) 1998-03-30
BG97446A (en) 1994-03-24
CZ279586B6 (cs) 1995-05-17
JP3094077B2 (ja) 2000-10-03
HU9300388D0 (en) 1993-04-28
CZ16693A3 (en) 1994-02-16
LTIP1714A (en) 1995-09-25
PT98688B (pt) 1999-01-29
PT98688A (pt) 1992-07-31
IE912818A1 (en) 1992-02-26
FI930608A (fi) 1993-02-11
IL99169A0 (en) 1992-07-15
WO1992003134A1 (en) 1992-03-05
AU657490B2 (en) 1995-03-16
LT3978B (en) 1996-06-25
NO930452D0 (no) 1993-02-09
US5385921A (en) 1995-01-31
NZ239329A (en) 1994-11-25
EP0619734A1 (de) 1994-10-19
EP0619734B1 (de) 1998-03-18
LV10921A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
FI913248A (fi) Kontrollerat frigoerande fast farmaceutisk doseringsform.
FI933248A (fi) Optiskt aktiva 5h-pyrrolo(3,4-b)pyrazinderat, dess framstaellning och farmaceutiska kompositioner innehaollande detta
MX9102473A (es) Agentes farmaceuticos.
DK1155695T3 (da) Anvendelse af en 1,3-oxathiolannukleosid-analog til fremstillingen af et lægemiddel til specifik indgivelse
DE69227407D1 (de) Superlumineszierende optische Quelle
DK1199307T3 (da) Farmaceutisk aktive benzoquinazolinforbindelser
DK0532595T3 (da) Farmakologisk anvendelse af visse cystinderivater
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
ITMI910456A0 (it) Composizione farmaceutica per il trattamento della cataratta
ATE164066T1 (de) Neue pharmazeutische formulierungen von 5-(2- chlor-1-hydroxyethyl)-4-methylthiazol
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
DE69115528D1 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE69119896D1 (de) Neue verwendung von bambuterol
RU93004984A (ru) Фармацевтическая композиция на основе 5(2-хлор-1-гидроксиэтил)-4-метилтиазола, применение 5-(2-хлор-1-гидроксиэтил)-4-метил-тиазола для лечения, способ лечения, соли 5-(2-хлор-1-гидроксиэтил)-4-метилтиазола
FI930967A (fi) Substituerade 6,7-dihydroimidazo(1,5,4-ef)(1,5)bensodiazepin-6-oner, deras framstaellning och farmaceutiska kompositioner
SE9000288D0 (sv) New use
MX9203359A (es) Nuevas composiciones farmaceuticas de insulina.
IT9022493A0 (it) Composizione farmaceutica a rilascio controllato contenente un sale farmaceuticamente accettabile di buflomedil
KR920007598U (ko) 의약용 캅셀
ITMI911049A1 (it) Composizione oftalmica
FI980376A0 (fi) N-/4-/5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yylimetyyli/-3-metoksibentsoyyli/-2-metyylibentseenisulfonamidin fysikaalista muotoa sisältävä farmaseuttinen koostumus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition